English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Nonalcoholic fatty liver disease (NAFLD), the spectrum of hepatic and extra-hepatic manifestations and complications resulting from the ectopic deposition of intra-hepatocyte fatty substrates, is a modern epidemic (1,2). NAFLD is not a problem restricted to the USA and/or Europe: compared to the estimated global prevalence of NAFLD, i.e., 25.24%, the Middle East (31.8%) and South America (30.5%) display even higher values while Africa ranks significantly below the global threshold (13.5%) but is not completely exempt from the NAFLD burden (2). These data clearly document that every practicing physician (not only hepatologists) in every corner of the world (not only in the western hemisphere) must/ should be culturally equipped to promptly identifying those individuals with suspected NAFLD. Physicians must be aware of the pathogenic determinants of disease and contrast them with tailored therapeutic interventions spanning from lifestyle changes, in all patients, to more personalized drug treatment (e.g., antidiabetic, statins, and other agents) in a variable proportion of patients. The paper by Barbara

Non-alcoholic fatty liver disease (NAFLD) diagnosis and management—differentiating the essential from the ancillary and the present from the future